eligibility_summary
Eligibility: histologically confirmed CD20+ DLBCL, relapsed/refractory after >=1 anti-CD20 regimen, ECOG 0-2, measurable disease, life expectancy >3 months, and either failed/ineligible/refused ASCT or ineligible/unable/unwilling for CAR-T, or relapsed after prior CAR-T. Exclude CNS involvement, prior CD3xCD20 bispecifics, prior R-GemOx/GemOx, or lenalidomide-refractory disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 3 R/R DLBCL trial comparing: (A) epcoritamab + lenalidomide vs (B) rituximab + gemcitabine + oxaliplatin, with an epcoritamab-only arm. Mechanisms/types: Epcoritamab—subcutaneous bispecific T‑cell–engaging antibody (CD3xCD20) that redirects cytotoxic T cells to CD20+ malignant B cells, inducing synapse formation and perforin/granzyme-mediated apoptosis. Lenalidomide—oral IMiD that binds cereblon, degrades IKZF1/3, enhances T- and NK-cell activation, modulates cytokines, and is anti-angiogenic/anti-lymphoma. Rituximab—IV anti-CD20 monoclonal antibody causing B-cell depletion via ADCC, CDC, and apoptosis. Gemcitabine—IV nucleoside analog antimetabolite inhibiting DNA synthesis. Oxaliplatin—IV platinum agent creating DNA crosslinks and apoptosis. Targets/pathways: CD20+ B cells, CD3 T-cell activation, cereblon/IKZF1/3 axis, Fc-mediated ADCC/CDC, DNA replication and damage-repair pathways.